Problem

Gamgee addresses the poor prognosis and limited treatment options facing dogs with cancer. Cancer affects roughly one in four dogs during their lifetime and is described as the leading cause of death in pets. The killer use case is a dog whose cancer has progressed despite conventional interventions: Gamgee began with Rosie, whose surgery, chemotherapy, and immunotherapy had failed and who was given months to live. More broadly, the company is tackling the biological and operational difficulty of matching treatment to tumors that mutate and differ from patient to patient.

The economic opportunity sits in a substantial and growing veterinary-oncology market, estimated at $1.57 billion globally in 2024 and projected to reach $3.11 billion by 2030. Gamgee's stated economic thesis is to turn bespoke cancer treatment from an artisanal process into a repeatable system that becomes faster and cheaper; its long-term development targets are a 24-hour turnaround and $2,000 per custom vaccine. Those are explicitly targets, not current availability or pricing, so the present pain is better understood as unmet clinical need and inefficient personalization than as a proven price point.

Product / Service

Gamgee is building an end-to-end platform for personalized mRNA cancer vaccines for dogs. A veterinary oncologist refers an eligible case, collects a tumor biopsy and matched blood sample during an already-planned procedure, and sends them through a prepaid kit. Gamgee performs whole-exome sequencing, compares tumor and healthy DNA, uses canine-specific AI models to rank tumor-specific neoantigens, prepares a design report for veterinary review, and then coordinates GMP manufacturing and cold-chain delivery of the vaccine.

The veterinarian remains in control of the clinical decision and administers the finished vaccine under existing clinical judgment, while Gamgee handles the work from sequencing through response monitoring. The vaccine encodes selected cancer-specific markers in mRNA so the dog's cells briefly display them and train a targeted immune response. The company reports an indicative roughly four-week path from sample return to vaccine in hand, with less than 20 minutes of clinician design-review time, and says its first documented case produced approximately 75% tumor reduction; these figures come from an early case and initial workflow rather than an established standard of care.

Market

Gamgee competes at the intersection of AI-native biotechnology, genomics, oncology, RNA therapeutics, and veterinary medicine, specifically personalized immunotherapy for companion animals. It is not the only canine-cancer immunotherapy effort: ELIAS Animal Health uses a protocol based on vaccinating a dog with its own cancer cells, while Calviri has launched a canine vaccine trial targeting early-stage hemangiosarcoma. These are adjacent competitors and alternatives rather than evidence that another company offers the same end-to-end, tumor-specific mRNA workflow.

The current gamgee.io company appears clinical-stage and pre-commercial rather than an established revenue business. Its site says it is running clinical trials in Australia and accepting applications globally; its veterinary page says it is enrolling an Australian 2026 trial and accepting referrals. Y Combinator lists the company as founded in 2026, active, with a two-person team, and reports that Gamgee is turning Rosie's one-off treatment into a repeatable clinical system. The available evidence does not disclose revenue, customers paying for treatment, or current pricing, so traction is best described as an early human-and-animal clinical proof point, trial enrollment, institutional collaboration, and an operating referral pipeline rather than demonstrated commercial scale.